<DOC>
	<DOCNO>NCT00469976</DOCNO>
	<brief_summary>RATIONALE : Enzastaurin may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , carboplatin gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving enzastaurin together carboplatin gemcitabine , without bevacizumab , may kill tumor cell . PURPOSE : This phase II trial study well give enzastaurin together carboplatin gemcitabine , without bevacizumab , work treat patient recurrent , stage IIIB , stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Enzastaurin , Carboplatin , Gemcitabine With Without Bevacizumab Treating Patients With Recurrent , Stage IIIB , Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival patient recurrent stage IIIB IV non-small cell lung cancer treat carboplatin , gemcitabine , enzastaurin without bevacizumab . Secondary - Determine toxicity regimen patient . - Determine overall survival patient treat regimen . - Determine response rate patient treat regimen . OUTLINE : This multicenter study . Patients assign 1 2 treatment group base eligibility bevacizumab therapy . - Group 1 ( bevacizumab-eligible ) : Patients receive carboplatin IV 30 minute bevacizumab IV 30-90 minute day 1 ; gemcitabine hydrochloride IV 30 minute day 1 8 ; oral enzastaurin hydrochloride 3 4 time daily day 1-21 course 1-6 bevacizumab IV 30-90 minute day 1 oral enzastaurin hydrochloride 3 time daily day 1-21 subsequent course . - Group 2 ( bevacizumab-ineligible ) : Patients receive carboplatin , gemcitabine hydrochloride , enzastaurin hydrochloride group 1 course 1-6 enzastaurin hydrochloride alone 3 time daily day 1-21 subsequent course . In group , course repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 5 year . PROJECTED ACCRUAL : A total 99 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIB ( confirm malignant pleural effusion ) , stage IV , recurrent disease Mixed tumor categorize predominant cell type allow provide small cell element exist Cytologic histologic element establish metastatic tumor aspirate biopsy Measurable disease define RECIST criterion No squamous cell carcinoma ( group 1 ) No history brain metastasis ( group 1 ) History treat brain metastasis allow provided patient take steroids antiseizure mediation ( group 2 ) PATIENT CHARACTERISTICS : ECOG performance status 01 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 mg/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN ( ≤ 5 time ULN liver metastasis ) AST ALT ≤ 3 time ULN ( ≤ 5 time ULN liver metastasis ) INR &lt; 1.5 PTT normal ( group 1 ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ( group 1 2 ) 6 month completion study treatment ( group 1 ) No preexist peripheral neuropathy ≥ grade 2 Must able swallow tablet No cardiovascular condition , include follow : Myocardial infarction within past 6 month Cerebrovascular ischemia stroke within past 6 month NYHA congestive heart failure &gt; class II Unstable angina pectoris Serious cardiac arrhythmia require medication Significant vascular disease Symptomatic peripheral vascular disease No concurrent medical condition , psychiatric illness , limitation would limit study compliance No ongoing active infection ongoing fever within past 6 month No history uncontrolled hypertension , define blood pressure ≥ 150/90 mm Hg despite stable regimen antihypertensive therapy No serious nonhealing wound , ulcer , bone fracture within past 4 week No ongoing active infection No history thrombotic hemorrhagic disorder , bleed diathesis , coagulopathy ( group 1 ) No bleed &gt; grade 2 bleed require intervention within past 4 week ( group 1 ) No history gross hemoptysis ( define &gt; ½ teaspoon bright red blood ) ( group 1 ) Urine protein : creatinine ( UPC ) ratio &lt; 1.0 spot urinalysis For UPC ratio &gt; 0.5 , 24hour urine protein must obtain urine protein level must &lt; 1,000 mg ( group 1 ) None follow condition ( group 1 ) : Grade II great peripheral vascular disease Abdominal fistula Gastrointestinal perforation Intraabdominal abscess No known hypersensitivity component bevacizumab ( group 1 ) No history hypertensive crisis hypertensive encephalopathy ( group 1 ) PRIOR CONCURRENT THERAPY : More 4 week since prior major surgical procedure More 7 day since prior minor surgical procedure No prior chemotherapy advanced NSCLC Postoperative adjuvant chemotherapy previously resect NSCLC allow last dose give &gt; 1 year ago More 3 week since prior radiation therapy recover More 3 week since prior immunotherapy and/or hormonal therapy ( include hormone replacement therapy contraceptive ) recover More 14 day since prior enzyme induce antiepileptic drug ( EIAEDs ) More 10 day since prior concurrent daily treatment acetylsalicylic acid ( &gt; 325 mg/day ) NSAIDs know inhibit platelet function chronic condition ( group 1 ) No concurrent major surgical procedure ( group 1 ) No concurrent carbamazepine , phenobarbital , phenytoin No concurrent therapeutic anticoagulation ( group 1 ) Prophylactic anticoagulation venous access device allow No concurrent treatment dipyridamole , ticlopidine , clopidogrel , cilostazol ( group 1 ) No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>